Why Actinogen Medical shares climbed 466% on excitement over an Alzheimer's treatment

An Alzheimer's treatment is one of medicine's last great frontiers.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Actinogen Medical Ltd (ASX: ACW) share price is up 466% today from 0.9 cents to 5.1 cents after the biotech researcher reported positive clinical trial results for its Xanamem drug designed to treat cognitive impairment in the elderly.

According to the company's announcement its trial reached a "statistically significant" endpoint in treating patients with 20mg daily dose of Xanamem for 12 weeks, compared to placebo.

Moreover, the company claims the printed dataset advances its drug development strategy for the treatment of Alzheimer's and other neurological diseases. 

Treating Alzheimer's is commonly described as one of the last great medical frontiers as it's one of the most prevalent human diseases still with no recognised treatment or cure.

As such share markets globally are littered with the shells of biotech hopefuls that have claimed to develop treatments only for trial results to prove ineffective. 

Back in March 2019 shares in US biotech giant Biogen crashed after it ended the trials into its own Alzheimer's drug that Goldman Sachs had previously told investors should generate US$12 billion a year in sales. Oops.

While shares in ASX listed Prana Biotechnology (ASX: PBT) went gangbusters to hit a high around $1.26 in 2014 only to sell for 3.3 cents today under a new name of Alterity Therapeutics Ltd (ASX: ATH).

Prana shares bombed after its much vaunted Phase II Alzheimer drug trials failed on almost every count. 

Some medical professionals have even claimed the the neuro-degenerative and genetic nature of Alzheimer's or Huntington's mean a treatment will never be found. 

As such we can see this is a high risk, but high reward space if any biotech ever does crack what is probably the largest unmet single medical market left. As you can probably guess I would not suggest buying Actinogen shares. 

Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned.You can find Tom on Twitter @tommyr345

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Businessman smiles with arms outstretched after receiving good news.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a lucrative return to trading for investors this Tuesday.

Read more »

Business man at desk looking out window with his arms behind his head at a view of the city and stock trends overlay.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

Warren Buffett
Share Market News

$10,000 invested in Berkshire Hathaway shares 5 years ago is now worth…

The past 5 years have been especially fruitful for Berkshire Hathaway investors.

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Share Fallers

Why Coronado Global, Genesis Minerals, Monash IVF, and Platinum shares are sinking today

These shares are starting the week in the red. But why?

Read more »

A man sits in a chair hunched over a laptop and covered head to toe in frozen icicles to represent Envirosuite's trading halt
Mergers & Acquisitions

Johns Lyng Group shares enter trading halt. Is it a takeover target?

This ASX 200 stock looks ripe for a takeover.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Share Gainers

Why Austal, Botanix, DroneShield, and NextDC shares are storming higher today

These shares are starting the week with a bang. But why?

Read more »

A female coal miner wearing a white hardhat and orange high-vis vest holds a lump of coal and smiles as the Whitehaven Coal share price rises today
Share Gainers

The Coronado Global share price just surged to a 114% weekly gain. Here's why

Investors have sent the ASX coal stock flying higher in June. But why?

Read more »

Two brokers pointing and analysing a share price.
Share Market News

Here are the ASX 20, ASX 50, ASX 100, and ASX 200 shares being added and kicked out of their indices

Let's see what changes are being made at this month's quarterly rebalance.

Read more »